SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that clinical data from its successful phase 2a trial of SM04690 for the treatment of knee osteoarthritis (OA) has been accepted as a poster presentation at the American Academy of Orthopaedic Surgeons (AAOS) 2019 Annual Meeting to be held in Las Vegas, from March 12-16, 2019.
“The data from this successfully-completed phase 2a study demonstrate that Samumed’s SM04690 has the potential to change the treatment paradigm for people suffering from knee osteoarthritis. I am excited these preliminary data will be shared with the members of the Academy at this year’s annual meeting,” said John A. Bergfeld, M.D., Samumed scientific advisory board member and Senior Surgeon, Department of Orthopaedic Surgery at the Cleveland Clinic.
Poster presentation details:
| Abstract Title | Date/Time | Session Title |
| A 52-Week, Randomized, Double-Blind, Phase 2 Study of an Intra-articular Wnt Pathway Inhibitor (SM04690) for Osteoarthritis | Tuesday, March 12 7:00 a.m. – 6:00 p.m. PST | P0111 – Adult Reconstruction Knee Poster Session I |
Further details can be found on the AAOS website at https://www.aaos.org/annualmeeting/. A copy of the presentation materials can be accessed by visiting the Publications section of the Samumed website following the conclusion of the conference.
About the American Academy of Orthopaedic Surgeons (AAOS) 2019 Annual Meeting
AAOS is the preeminent provider of musculoskeletal education to orthopaedic surgeons and others in the world. Its world-renowned annual meeting provides medical education activities, creating a forum for the presentation of basic and clinical research with current as well as future potential applications in the management of patients with musculoskeletal disease or injury. The annual meeting helps to strengthen professional relationships and develop networks that lead to better patient care, individual surgeon career satisfaction, and a more robust profession as a whole.
About Osteoarthritis
Arthritis is the leading cause of adult disability. As the most common type of arthritis, osteoarthritis (OA) is characterized by the destruction of articular cartilage and structural changes in bone, which contribute to pain and loss of joint function. An estimated 30 million US adults suffer from OA, primarily due to an aging population and an increasing prevalence of obesity. The combination of direct medical costs, pain and suffering, and loss of workplace productivity elevates OA to a major socioeconomic problem for health systems, the economy, and suffering patients. Current treatment options for patients are palliative in nature with no approved disease-modifying agents available to patients.
About SM04690
SM04690 is a small-molecule inhibitor of the Wnt pathway administered as an intra-articular injection and in development as a potential disease-modifying drug for osteoarthritis (DMOAD). Vehicle-controlled preclinical data suggested that SM04690 has a dual mechanism of action with three effects on joint health – generation of cartilage, slowing down of cartilage breakdown, and reduction of inflammation. There are currently no approved disease-modifying treatments for osteoarthritis. Additional information on Samumed’s SM04690 osteoarthritis program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=20.
About Samumed
Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. Learn more about Samumed’s potential regenerative drug candidates and broad clinical pipeline at https://www.samumed.com/pipeline/default.aspx.
Corporate Contact:
Erich Horsley
Samumed, LLC
erich@samumed.com
858-365-0200
Investor Contact:
Ashley Robinson
LifeSci Advisors
arr@lifesciadvisors.com
617-535-7742
Media Contact:
Josephine Belluardo, Ph.D.
LifeSci Public Relations
jo@lifescipublicrelations.com
646-751-4361